Supplier News: Fujifilm Biosciences, Incog Biopharma, Alcami & More
The latest from CDMOs, CMOs, and suppliers featuring Fujifilm Biosciences/Chitose, Incog BioPharma Solutions, Alcami, Artis BioSolutions/Syngoi Technologies, Gaelic Laboratories/Athlone Laboratories, Halo Pharma, Sharp Sterile Manufacturing and GBI Manufacturing.
Biologics Manufacturing
* Fujifilm Biosciences, Chitose Partner for Cell Line Development
* Artis BioSolutions To Acquire Syngoi Technologies
Formulation Development/Drug Product Manufacturing
* Incog Biopharma To Invest $200 M To Expand Injectable Drug Product Mfg Capacity
* Alcami Adds New Fill–Finish Line at US Mfg Site
* Gaelic Laboratories Acquires Athlone Laboratories
* Halo Pharma Adds New Roller Compactor to New Jersey Facility
* Sharp Sterile Manufacturing Investing $28 M in Fill-Finish Facility
Appointments
* GBI Manufacturing Appoints New President
Biologics Manufacturing
Fujifilm Biosciences, Chitose Partner for Cell Line Development
Fujifilm Biosciences, formerly Fujifilm Irvine Scientific, a provide of cell-culture media and reagents, recombinant growth factors and proteins, specialty chemicals, and assays, and Chitose Laboratory, which provides cell-line development services, have announced a new strategic alliance focused on cell-line development.
Chitose will use its proprietary CHO-MK cell line and high-expression vector system, which enable productivity and scalability for antibody and recombinant protein production. Fujifilm will utilize its GMP manufactured cell culture AdaptPD CHO-MK platform media, designed to optimize CHO-MK cell growth and productivity across diverse bio/pharmaceutical applications.
Source: Fujifilm Biosciences
Artis BioSolutions To Acquire Syngoi Technologies
Artis BioSolutions, a San Diego, California-based advanced-therapies development and manufacturing company, has agreed to acquire Syngoi Technologies, a Bilbao, Spain-based company providing enzymatic-based synthetic DNA manufacturing capabilities.
The acquisition will advance Artis’ strategy of building a differentiated platform to accelerate gene-to-drug discovery across a range of therapeutic modalities by adding fast and cost-effective enzymatic-based synthetic DNA manufacturing capabilities. Following closing, Artis will establish a US operating presence for Syngoi’s technology through its wholly-owned entity, Landmark Bio, a Watertown, Massachusetts-based CDMO of cell and gene therapies. Syngoi’s European GMP-ready facilities in Bilbao, Spain will become a central component of Artis’ global footprint. Artis will also continue to invest in Syngoi’s operations and team in Bizkaia, Spain.
The transaction is expected to close in the first quarter of 2026, subject to customary regulatory approvals and closing conditions. Financial terms were not disclosed.
Source: Artis BioSolutions
Formulation Development/Drug Product Manufacturing
Incog Biopharma To Invest $200 M to Expand Injectable Drug Product Mfg Capacity
Incog BioPharma Services, a CDMO specializing in sterile injectables, has announced an investment of approximately $200 million in its manufacturing facility in Fishers, Indiana, to increase the company’s injectable drug-product manufacturing capacity.
The expansion is scheduled to begin in early 2026, establishing the 21‑acre campus as a global manufacturing hub for injectable biopharmaceuticals, with 300,000 square feet of space. By 2030, Incog expects to employ nearly 1,000 people at its Fishers campus.
Source: Incog BioPharma Services
Alcami Adds New Fill-Finish Line at US Mfg Site
Alcami, a CDMO of drug products and provider of analytical testing services, has announced the GMP readiness of a third sterile fill-finish line at its Research Triangle Park, North Carolina, campus.
This is the company’s fifth sterile fill–finish line that is qualified for GMP clinical and commercial manufacturing within Alcami’s drug-product manufacturing network. The newest line includes an automated grade A isolator fill line, designed to deliver filling, stoppering, and capping under aseptic conditions. The new line supports a range of vial formats, from 2R to 30R and is equipped for liquid and lyophilization products, from early-stage clinical development to full-scale commercial production in vials and pre-filled syringes.
Source: Alcami
Gaelic Laboratories Acquires Athlone Laboratories
Gaelic Laboratories has acquired Athlone Laboratories; both companies manufacture beta-lactam antibiotics.
Gaelic Laboratories manufactures beta-lactam products in tablets, capsules, and powders for suspension forms. It provides its own beta-lactam products under the Gaelic Laboratories brand and also provides contract manufacturing and packaging services. Athlone develops and manufactures oral beta-lactams for partnered companies.
Source: Gaelic Laboratories
Halo Pharma Adds New Roller Compactor to New Jersey Facility
Halo Pharma, a Whippany, New Jersey-based CDMO, is expanding its manufacturing capabilities at its Whippany, New Jersey, facility, with the addition of a Gerteis Macro-Pactor roller compactor. It is expected to be online in the first quarter of 2026.
Source: Halo Pharma
Sharp Sterile Manufacturing Investing $28 M in Fill-Finish Facility
Sharp Sterile Manufacturing, a a CDMO of fill-finish services, has announced a $28-million expansion of its fill-finish site in Lee, Massachusetts. The expansion will more than double the facility’s filling capacity through the installation of a new fully automated IMA Life isolated filling line for ready-to-use vials. The system integrates advanced robotics, non-destructive weight checks, and a lyophilizer to produce batches up to 100,000 units.
Source: Sharp Sterile Manufacturing
Appointments
GBI Manufacturing Appoints New President
GBI Biomanufacturing, a Fort Lauderdale, Florida-based CDMO of biologics drug substance and fill-finish services, has appointed Jesse McCool, Ph.D., currently Chief Scientific Officer at Bionova Scientific, as President. He brings more than two decades of leadership experience spanning process development and clinical & commercial GMP manufacturing in biologics, plasmids and advanced therapies with scientific expertise in microbial and mammalian production platforms.
Source: GBI Manufacturing
